Mylan, the profiteering, tax-dodging drug company currently taking immense heat for jacking up the price of its Epipen by 500%, announced Thursday that it will help more patients cover their ...

Mylan's generic version will hit shelves within several weeks at a list price of $300 for a two-pack carton in dosages of either 0.15 milligrams or 0.30 mg, the company said.

Mylan benefited from factors including failed competitors, patent protections and laws requiring allergy medications in schools. Having a virtual monopoly has facilitated the rapid price hike.

Mylan, which showered itself in infamy by jacking up the price of its EpiPen, a potentially life-saving epinephrine injector, by 500% over less than a decade, announced Friday that it is finally ...

Mylan Inc., based in suburban Pittsburgh, became Netherlands-based Mylan N.V. last year to reduce its U.S. income taxes. But when you take a close look at Mylan’s business, ...

Mylan raised EpiPen prices "to get filthy rich at the expense of our constituents," Rep. Elijah Cummings, D-Md., said at the House Oversight Committee hearing. Bresch, however, ...

Mylan CEO Heather Bresch said she shared Americans’ frustration with the spiraling cost of drugs like her company’s EpiPen in a CNBC interview Thursday morning, but her comments hew closely to ...

Mylan on Monday said it would launch a generic alternative to EpiPen at a 50% discount after being criticized for dramatically raising the price of the lifesaving drug.

Mylan NV is poised to lose its hostile bid for Perrigo Co., people familiar with the matter said, a rare outcome in one of the bitterest takeover battles in decades.

Mylan bought the rights to EpiPen in 2007. It started sharply increasing the cost of the device when it seemed that a generic version was set to enter the market, potentially cutting into its profits.

Mylan is marketing a long-acting version of the best-selling Lantus insulin — which the company named Semglee — for adults with Type 2 diabetes, and adults and children with Type 1 diabetes.